Im concerned any background research by instos would highlight DNDN performance.
You would think the drop in SP lately could scare any major investment here too.
If only DNDN didnt get thown out like it did. FYI it is now half of pre nasdaq aprovel levels.
How only hope is that PRR is not like DNDN but unique in the fact it has global coverage and more than one product. with better future potential.
Time will tell and thats why I dont think this will get back to 40c soon. Instos do do research
prima biomed and it's inclusion to the asx300, page-8
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.020(5.63%) |
Mkt cap ! $508.4M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.8¢ | 33.5¢ | $1.217M | 3.495M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 80427 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 183494 | 1 |
View Market Depth
| Last trade - 15.59pm 17/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |